
|Videos|April 23, 2022
Study: Effects of two dosing regimens of Netarsudil in patients with Fuchs corneal dystrophy
Author(s)Sheryl Stevenson
Richard L. Lindstrom, MD, of Minnesota Eye Consultants, discusses his ASCRS presentation, "Randomized, Open-Label, Parallel-Group Study of Two Dosing Regimens of Netarsudil in Patients with Fuchs Corneal Dystrophy," with Ophthalmology Times' Sheryl Stevenson.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA clears BVI’s FineVision HP trifocal IOL for the US market
2
Treating myopia today: US-focused treatments, challenges, and global insights
3
US FDA awards Epion Therapeutics EpiSmart cross-linking system Fast Track designation
4
Abeona Therapeutics’ ABO-503 chosen for FDA's Rare Disease Endpoint Advancement Pilot Program
5